Articles tagged with: Secondary Cancer
The European Medicines Agency announced earlier today that its Committee for Medicinal Products for Human Use has completed its safety review of Revlimid. The review was started earlier this year after several studies showed an increased risk of new cancers in newly diagnosed multiple myeloma patients being treated with Revlimid (lenalidomide) and other treatments.
The Agency’s Committee has concluded that “the benefits of Revlimid, particularly improved survival, continue to outweigh the risks but recommended that the prescribing information for Revlimid be updated with a warning and advice to …
Results of a large analysis conducted in Sweden show that multiple myeloma patients are more likely than the general population to develop certain cancers, including acute myeloid leukemia, myelodysplastic syndromes, and non-melanoma skin cancer.
Furthermore, the researchers found that patients with the myeloma precursor disease monoclonal gammopathy of undetermined significance (MGUS) also have a greater risk of developing these cancers than the general population.
Like myeloma patients, MGUS patients have abnormal proteins in the blood as a result of defective plasma cells in the bone marrow. However, unlike myeloma patients, …
Monday was the fourth day of the American Society of Clinical Oncology (ASCO 2011) annual meeting in Chicago. Although the meeting concluded yesterday, Monday was the last day of the meeting that contained any myeloma-relevant material.
The morning started with a session recapping highlights of the meeting from Sunday. Dr. Ivan Borello from the Johns Hopkins University School of Medicine was invited to give a 15-minute presentation recapping the myeloma highlights (see Part 1 and Part 2 of The Beacon’s Day Three update for more information).
The rest …
Three myeloma experts yesterday presented additional clinical trial data on the possible link between Revlimid and secondary cancer in multiple myeloma patients. All three experts concluded that Revlimid’s benefit as a myeloma treatment outweighs its risks.
The presentations were made at a session of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
In a summary talk reviewing the three presentations, Dr. Ola Landgren from the U.S. National Cancer Institute noted that the risk of developing a secondary cancer following Revlimid (lenalidomide) therapy was significantly lower than …
Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with presentations related to multiple myeloma.
There was a morning session where a total of eight research abstracts were presented and discussed. Then, late in the afternoon, there was an education session focused on multiple myeloma, with several different presentations.
The presentations during the morning session were on three different topics: Revlimid (lenalidomide) and its potential link to secondary cancer; myeloma bone disease; and new drugs being developed …